Lehne's Pharmacology for Nursing Care 10th Edition TEST
BANK(Chapter 1-110).
Chapter 3: Drug Regulation, Development, Names, and Infor
7 c 7 c 7 c 7 c 7 c 7 c 7 c
mat ion Test Bank
7c 7 c 7 c
MULTIPLE 7 c CHOICE
1. A nurse educator is conducting a
7 c continuing education class on pharmacology.
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7
cTo evaluate the learning of the nurses in the class, the nurse educato
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
r asks, ―Whi ch drug name is a generic drug name?‖ Which is the
7 c 7 c 7c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7
c correct response? a. Acet aminophen 7 c 7 c 7 c 7c
b. Tylenol
c. Cipro
d. Motrin
ANS: A 7 c
Acetaminophen is the generic name. Tylenol, Cipro, and Motrin are all trade nam 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
es.
DIF: Cognitive Level: Comprehension REF: Table 3-
7 c 7 c 7 c 7c7c 7 c 7 c
3: The Three Types ofs2Drug Names TOP: Nursing Process: Diagnosis
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
MSC: NCLEX Client Needs Category: Physiologic Integrity: Pharmacologic and Parenteral T
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
herap ies 7 c
2. The FDA Amendments Act (FDAAA) was passed in 2007 to address
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7
c which as pect of dr ug safety? 7 c 7c 7 c 7 c 7 c 7 c
a. Allowing pharmaceutical companies to identif 7 c 7 c 7 c 7 c
y off- 7c
label uses ofs2medications approved for othe 7 c 7 c 7 c 7 c 7 c
rs uses 7 c
b. Evaluating drug safety information that emerges after a drug has b 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
een appr oved and is in use 7 c 7c 7 c 7 c 7 c 7 c
c. Expediting the approval process of the U.S. Food and Drug Admi 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
nistration (FDA) s o that needed drugs can get to market more 7c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
quickly
d. Requiring manufacturers to notify patients before removing a drug from
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c t
he mark et 7 c 7c
ANS: 7 c B
The FDAAA was passed to enable the Food and Drug Administration to
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
7 continue oversight
c 7c
ofs2a drug after granting it approval so that changes in labeling 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7
ccould be 7 c
made as necessary 7 c 7 c
, and postmarketing risks could be tracked and identified. 7 c 7 c 7 c 7 c 7 c 7 c 7 c
7 A pr ovision ofs2the FDA Moderniza tion Act (FDAMA), passed in 199
c 7 c 7c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
7, allows drug c ompanies to promote their products for of f-
7 c 7 c 7 c 7c 7 c 7 c 7 c 7 c 7 c 7 c
label uses as long as they promise to conduct studies to support their c
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
laims. Regu lations to permit accelerated approval ofs2drugs for life-
7 c 7c 7 c 7 c 7 c 7 c 7 c 7 c
,Test Bank Lehne's Pharmacology for Nursing Care, 11th E d
7c 7c 7c 7c 7c 7c 7c 7c 7c
i tion by Jacqueline Burchum, Laura Rosenthal Chapter
7 c 7 c 7 c 7 c 7 c 7 c 7 c
threatening diseasess2weres2adopteds2ins21992s2bys2thes2FDA.s2The requirement that drug
compani
1- 7 c 7 c 7 c 7 c
es notify112|Complete
patientss26 months Guide 7 A+
before removing
c a drug from the
7 c 7 c 7 c 7 7c c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
market is a provision ofs2the F DAMA.
7 c 7c 7 c 7 c 7 c 7 c
DIF: Cognitive 7 c 7 c Level: 7 c Comprehe
ns ion7c REF: 7 c Landmark Drug Legislation
7 c 7 c
TOP: Nursing Process: Evaluation
7 c 7 c 7 c7 c 7 c 7 c
MSC: NCLEX Client Needs Category:
7 c 7 c 7 c 7 c 7 c Physiologic 7 c Integrity: 7 c Pharmacologic 7 c and 7 c Paren
teral Th erapies
7 c 7c
, 3. A nursing student asks a nurse about pharmaceutical research and wants
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7
c to know the purpo se of
7 c 7c randomization in
7 c 7 c 7 c 7 c
drug trials. The nurse explains that
7 c 7 c 7 c
randomi zation is used to: 7c 7 c
a. ensure that differences in outcomes are the result ofs2treatment an
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
d not di fferences in subjects.
7 c 7 c 7c 7 c 7 c
b. compare the outcome caused by the treatment to the outcome caused
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c b
y no treat ment.
7 c 7 c 7c
BANK(Chapter 1-110).
Chapter 3: Drug Regulation, Development, Names, and Infor
7 c 7 c 7 c 7 c 7 c 7 c 7 c
mat ion Test Bank
7c 7 c 7 c
MULTIPLE 7 c CHOICE
1. A nurse educator is conducting a
7 c continuing education class on pharmacology.
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7
cTo evaluate the learning of the nurses in the class, the nurse educato
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
r asks, ―Whi ch drug name is a generic drug name?‖ Which is the
7 c 7 c 7c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7
c correct response? a. Acet aminophen 7 c 7 c 7 c 7c
b. Tylenol
c. Cipro
d. Motrin
ANS: A 7 c
Acetaminophen is the generic name. Tylenol, Cipro, and Motrin are all trade nam 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
es.
DIF: Cognitive Level: Comprehension REF: Table 3-
7 c 7 c 7 c 7c7c 7 c 7 c
3: The Three Types ofs2Drug Names TOP: Nursing Process: Diagnosis
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
MSC: NCLEX Client Needs Category: Physiologic Integrity: Pharmacologic and Parenteral T
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
herap ies 7 c
2. The FDA Amendments Act (FDAAA) was passed in 2007 to address
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7
c which as pect of dr ug safety? 7 c 7c 7 c 7 c 7 c 7 c
a. Allowing pharmaceutical companies to identif 7 c 7 c 7 c 7 c
y off- 7c
label uses ofs2medications approved for othe 7 c 7 c 7 c 7 c 7 c
rs uses 7 c
b. Evaluating drug safety information that emerges after a drug has b 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
een appr oved and is in use 7 c 7c 7 c 7 c 7 c 7 c
c. Expediting the approval process of the U.S. Food and Drug Admi 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
nistration (FDA) s o that needed drugs can get to market more 7c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
quickly
d. Requiring manufacturers to notify patients before removing a drug from
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c t
he mark et 7 c 7c
ANS: 7 c B
The FDAAA was passed to enable the Food and Drug Administration to
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
7 continue oversight
c 7c
ofs2a drug after granting it approval so that changes in labeling 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7
ccould be 7 c
made as necessary 7 c 7 c
, and postmarketing risks could be tracked and identified. 7 c 7 c 7 c 7 c 7 c 7 c 7 c
7 A pr ovision ofs2the FDA Moderniza tion Act (FDAMA), passed in 199
c 7 c 7c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
7, allows drug c ompanies to promote their products for of f-
7 c 7 c 7 c 7c 7 c 7 c 7 c 7 c 7 c 7 c
label uses as long as they promise to conduct studies to support their c
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
laims. Regu lations to permit accelerated approval ofs2drugs for life-
7 c 7c 7 c 7 c 7 c 7 c 7 c 7 c
,Test Bank Lehne's Pharmacology for Nursing Care, 11th E d
7c 7c 7c 7c 7c 7c 7c 7c 7c
i tion by Jacqueline Burchum, Laura Rosenthal Chapter
7 c 7 c 7 c 7 c 7 c 7 c 7 c
threatening diseasess2weres2adopteds2ins21992s2bys2thes2FDA.s2The requirement that drug
compani
1- 7 c 7 c 7 c 7 c
es notify112|Complete
patientss26 months Guide 7 A+
before removing
c a drug from the
7 c 7 c 7 c 7 7c c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
market is a provision ofs2the F DAMA.
7 c 7c 7 c 7 c 7 c 7 c
DIF: Cognitive 7 c 7 c Level: 7 c Comprehe
ns ion7c REF: 7 c Landmark Drug Legislation
7 c 7 c
TOP: Nursing Process: Evaluation
7 c 7 c 7 c7 c 7 c 7 c
MSC: NCLEX Client Needs Category:
7 c 7 c 7 c 7 c 7 c Physiologic 7 c Integrity: 7 c Pharmacologic 7 c and 7 c Paren
teral Th erapies
7 c 7c
, 3. A nursing student asks a nurse about pharmaceutical research and wants
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7
c to know the purpo se of
7 c 7c randomization in
7 c 7 c 7 c 7 c
drug trials. The nurse explains that
7 c 7 c 7 c
randomi zation is used to: 7c 7 c
a. ensure that differences in outcomes are the result ofs2treatment an
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c
d not di fferences in subjects.
7 c 7 c 7c 7 c 7 c
b. compare the outcome caused by the treatment to the outcome caused
7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c 7 c b
y no treat ment.
7 c 7 c 7c
